Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P83111
UPID:
LACTB_HUMAN
Alternative names:
-
Alternative UPACC:
P83111; P83096
Background:
Serine beta-lactamase-like protein LACTB, located in the mitochondria, plays a pivotal role in regulating mitochondrial lipid metabolism. It achieves this by modulating the protein levels of PISD, a key enzyme in the conversion of phosphatidylserine to phosphatidylethanolamine, thus influencing mitochondrial lipid composition and function.
Therapeutic significance:
Understanding the role of Serine beta-lactamase-like protein LACTB could open doors to potential therapeutic strategies. Its function as a tumor suppressor, particularly in inhibiting the proliferation of various breast cancer cells, underscores its potential in cancer therapy by targeting mitochondrial lipid metabolism.